von Blomberg, Anemone
Kay, Lara
Knake, Susanne
Fuest, Sven
Zöllner, Johann Philipp
Reif, Philipp S.
Herrmann, Eva
Balaban, Ümniye
Schubert-Bast, Susanne
Rosenow, Felix
Strzelczyk, Adam
Article History
First Online: 26 March 2020
Compliance with Ethical Standards
:
: This study was supported by a LOEWE Grant from the State of Hessen for the “Center for Personalized Translational Epilepsy Research” (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany. There is no industry funding to report. Open Access funding provided by Projekt DEAL.
: AvB, SF, EH, and ÜB do not report any conflicts of interest. LK reports non-financial support from Eisai and UCB. SK reports honoraria for speaking engagements from Desitin and UCB as well as educational grants from AD Tech, Desitin Arzneimittel, Eisai, GW, Medtronic, Novartis, Siemens, and UCB. JPZ reports a speaker’s honorarium from Eisai. PSR reports speaking honoraria from Eisai and honoraria from Austrian Institute of Technology (AIT). SSB reports personal fees from UCB Pharma, Eisai, Desitin Pharma, LivaNova, and Zogenix. FR reports personal fees from Eisai, grants and personal fees from UCB, grants and personal fees from Desitin Pharma, personal fees and other from Novartis, personal fees from Medtronic, personal fees from Cerbomed, personal fees from ViroPharma and Shire, grants from the European Union, and grants from the Deutsche Forschungsgemeinschaft. AS reports personal fees and grants from Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, LivaNova, Marinus Pharmaceuticals, Medtronic, Sage Therapeutics, UCB Pharma, and Zogenix.
: The study was approved by the ethics committee of the Goethe-University Frankfurt in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was waived by the ethics committee of the Goethe-University Frankfurt due to the retrospective nature of this study.